Emmanuelle Boutmy

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 9

Top Venues

Journal of comparative effectiveness research

Clinical epidemiology

Therapeutics and clinical risk management

International journal of clinical practice

Merck KGaA

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Merck KGaA Oct 04 2016

Germany

Associate Director Biostatistics :: Global Biostatistics, Epidemiology and Medical Writing

Publications

Pauline Bosco-Levy, Emmanuelle Boutmy, Estelle Guiard, Caroline Foch, Régis Lassalle, Clélia Favary, Meritxell Sabidó, Patrick Blin
Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case-control study within the French nationwide claims database. Pharmacoepidemiology and drug safety (2023)
Caroline Foch, Arthur Allignol, Thilo Hohenberger, Emmanuelle Boutmy, Stephan Schaefer, Ulrike Hostalek-Gottwald
Effectiveness of bisoprolol versus other β-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink. Journal of comparative effectiveness research 11 (6) (2022)
Kerstin M G Brand, Judith Schlachter, Caroline Foch, Emmanuelle Boutmy
Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database. Therapeutics and clinical risk management 18 (2022)
Dina Oksen, Patricia Prince, Emmanuelle Boutmy, Elizabeth M Garry, Barbara Ellers-Lenz, Adina Estrin, Andreas Johne, Patrice Verpillat, Nicolle M Gatto
Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study. Clinical and translational science 15 (8) (2022)
Caroline Foch, Arthur Allignol, Ulrike Hostalek-Gottwald, Emmanuelle Boutmy, Thilo Hohenberger
Real-World Effectiveness of Beta-Blockers versus Other Antihypertensives in Reducing All-Cause Mortality and Cardiovascular Events. International journal of clinical practice 2022 (2022)
Signe Sørup, Bianka Darvalics, Jakob Schöllhammer Knudsen, Anne Staub Rasmussen, Cathrine Fonnesbech Hjorth, Søren Viborg Vestergaard, Azza Ahmed Khalil, Leo Russo, Dina Oksen, Emmanuelle Boutmy, Patrice Verpillat, Mikael Rørth, Deirdre P Cronin-Fenton
Identifying Valid Algorithms for Number of Lines of Anti-Neoplastic Therapy in the Danish National Patient Registry Among Patients with Advanced Ovarian, Gastric, Renal Cell, Urothelial, and Non-Small Cell Lung Cancer Attending a Danish University Hospital. Clinical epidemiology 14 (2022)
Signe Sørup, Bianka Darvalics, Azza Ahmed Khalil, Marianne Nordsmark, Mette Hæe, Frede Donskov, Mads Agerbæk, Leo Russo, Dina Oksen, Emmanuelle Boutmy, Patrice Verpillat, Deirdre P Cronin-Fenton
Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation. Clinical epidemiology 13 (2021)
Chris P Pescott, Emmanuelle Boutmy, Michael Batech, Philippe Ronga, Francois-Xavier Lamy
Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer. Journal of comparative effectiveness research 10 (5) (2021)
Francois-Xavier Lamy, Michael Batech, Emmanuelle Boutmy, Philippe Ronga, Shaista Salim, Chris P Pescott
Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population. Journal of comparative effectiveness research 9 (16) (2020)

Emmanuelle Boutmy.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Emmanuelle Boutmy